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Background: The goal of this study was to determine the association of multiple antibiotic-resistant Pseudomonas aeruginosa (MARPA) acquisi-
tion with lung function decline in patients with cystic ﬁbrosis (CF).
Methods: Using data from Epidemiologic Study of Cystic Fibrosis (ESCF), we identiﬁed patients with spirometry data and MARPA, deﬁned as PA
(1) resistant to gentamicin and either tobramycin or amikacin, and (2) resistant to ≥1 antipseudomonal beta lactam. MARPA had to be detected in
a respiratory culture after ≥2 years of PA-positive but MARPA-negative respiratory cultures. Multivariable piecewise linear regression was per-
formed to model the annual rate of decline in forced expiratory volume in 1 second (FEV1) % predicted 2 calendar years before and after the index
year of MARPA detection, adjusting for patient characteristics and CF therapies.
Results: In total, 4349 patients with chronic PA and adequate PFT data were identiﬁed; 1111 subsequently developed MARPA, while 3238 pa-
tients were PA positive but MARPA negative. Compared with patients who did not acquire MARPA, MARPA-positive patients had lower
FEV1 and received more oral (pb0.013) and inhaled (pb0.001) antibiotic therapy. Mean FEV1 decline did not change signiﬁcantly after
MARPA detection (−2.22% predicted/year before detection and −2.43 after, p=0.45). There was no relationship between persistent infection
or FEV1 quartile and FEV1 decline.
Conclusions: Newly detected MARPA was not associated with a signiﬁcant change in the rate of FEV1 decline. These results suggest that MARPA
is more likely to be a marker of more severe disease and more intensive therapy, and less likely to be contributing independently to more rapid lung
function decline.
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Chronic bacterial endobronchial infection is a fundamental
feature of cystic fibrosis (CF) lung disease [1]. Antibiotics are
cornerstones of CF therapy, but their use is associated with
the detection of resistant organisms. Although patients with
CF can be infected with a variety of organisms, the most com-
mon organism, especially in older patients, is Pseudomonas
aeruginosa (PA) [2]. The prevalence of multiple antibiotic-re-
sistant PA (MARPA) has been shown to have increased 40%
from 1998 to 2002 [2]. The relationship between MARPA in-
fection and lung function in patients with CF is unclear.
Block et al. identified risk factors for pulmonary exacerbations
in CF patients infected with multi-resistant bacteria, but they
did not compare this group with patients who did not harbor
MARPA [3]. Davies et al. studied the prevalence and persis-
tence of MARPA infection in the pediatric CF population, but
they did not analyze outcomes associated with MARPA infec-
tion [4]. In one study, the presence of MARPA was associated
with more rapid decline in lung function, but this was a single-
center study of adult patients with CF performed at a site whose
patient population also included many patients referred for lung
transplantation [5]. These features limit the ability to generalize
their results to the CF population at large. More importantly,
the study was not designed to assess the impact of incident de-
tection of MARPA on subsequent lung function. Because of the
importance of PA infection in CF and concerns about antibiotic
resistance, determining whether incident MARPA is associated
with lung function decline would be of value.
It has been demonstrated that the decline in lung function
seen in CF patients is associated with pulmonary exacerbations
[6,7]. Exacerbations are frequently treated with intravenous an-
tibiotics directed at the organisms detected by respiratory cul-
ture, most commonly PA [1]. The increasing emergence of
MARPA raises the concern that antibiotic treatment of infec-
tions may be less effective, leading to accelerated loss of lung
function. On the other hand, there is increasing evidence of
poor correlation between resistance patterns and response to an-
tibiotic therapy for pulmonary exacerbation [8–10]. This would
imply that incident MARPA would not be a risk factor for ac-
celerated lung function decline. To gain further insight into
this issue, we used data from the Epidemiologic Study of Cystic
Fibrosis (ESCF), a large observational study of patients with
CF in North America [11], to assess the effect of incident detec-
tion of MARPA on lung function decline.
2. Methods
2.1. Study design
We performed an analysis of data from the ESCF, a longitu-
dinal cohort study. Data collected from 1994 to 2005 were used
for this analysis. Details of the design and implementation of
ESCF have previously been described [11]. Data were reported
from every patient encounter and included pulmonary function
tests (PFTs), anthropometric measures, clinical findings, respi-
ratory tract cultures, other medical conditions (e.g., asthma),and use of therapies. Informed consent was obtained according
to decisions by a local or central human subjects review board
(Copernicus Group tracking number OVA1-03-008).2.2. Cohort definition
To be included in the analysis, patients had to be at least
6 years old and have at least one respiratory tract culture per
year for a consecutive 5-year period. A consistent definition
was used from 1994 to 2005, in which study sites were
instructed to indicate MARPA if PA was found to meet both
of the following criteria: (1) resistant to gentamicin and either
tobramycin or amikacin and (2) resistant to one or more of
the following antipseudomonal beta lactam antibiotics: ticarcil-
lin, pipercillin, ceftazidime, aztreonam, and imipenem. Quino-
lones were not considered. For those laboratories where
gentamicin was not tested, gentamicin resistance was assumed.
Participants who had MARPA detected at any time during the
observation period (1996–2003) and who had cultures negative
for MARPA in the prior 2 years were considered incident
MARPA cases (MARPA+). The date that MARPA was first
reported was considered the date point for the subsequent anal-
ysis of pulmonary function decline. Each patient had to have a
minimum of 3 PFTs spanning a minimum time of 6 months
during the 2 years preceding and 2 years following the index
year, resulting in a total period of 5 years (Fig. 1). To account
for short-term changes in pulmonary function that could result
if treatment were immediately changed following a first-time
MARPA-positive culture, we defined an exclusion period com-
posed of the 90 days before and after the index date from which
PFT results were excluded from the primary analysis. PFTs
obtained during this exclusion period did not count towards
the minimum of 3 required to be in the analysis.
To allow comparisons between patients who acquired
MARPA and those who did not, we also analyzed a comparison
group of MARPA-negative patients composed of patients
≥6 years old who had PA but did not have any MARPA-
positive cultures during the a 5-year period that satisfied the
PFT criteria described above. The index date for these patients
was defined as the date of the culture closest to July 1 of the
index year. For MARPA-negative patients who were eligible
for multiple index years, the most central index year was cho-
sen if applicable; if 2 years were equally central, 1 was chosen
at random as the index year.2.3. Statistical analysis plan
The primary outcome measure for the analysis was the
forced expiratory volume in 1 second (FEV1). Values for
FEV1% predicted were calculated using reference equations
from Wang et al. for males through age 17 years and for fe-
males through age 15 years and from Hankinson et al. for pa-
tients over these ages [12,13]. Spirometry data were matched
with the data from the closest encounter within 14 days in
order to obtain encounter-level covariates. If no encounters
were present within the 14-day window, data from the most
Fig. 1. Culture and PFT criteria for inclusion into the analysis cohort.
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covariates.
A previous ESCF analysis showed that sites whose median
FEV1 was in the highest quartile tended to use more antibiotics,
especially intravenous antibiotics, compared with sites in the
lowest quartile [14]. This same analysis also showed that
these upper-quartile sites also had more MARPA. Since in-
creased antibiotic use was associated with an increased likeli-
hood of antibiotic resistance in this previous ESCF analysis
and in other studies [15,16], we stratified sites based on median
FEV1% predicted at each site using the same approach as pre-
viously described [14] and studied the impact of MARPA de-
tection on FEV1 decline by site quartile.
Standard descriptive statistics were used to characterize the
MARPA-positive and negative patients, with t tests and chi-
square tests used to compare the two groups during the time pe-
riods pre- and post-index culture and during the exclusion period.
Repeated-measures multivariable piecewise linear regression
models were generated to examine the rate of decline in
FEV1% predicted before and after the exclusion period. Patient-
level covariates included in the models were gender and age at
index culture, while encounter-level covariates included in the
models were gender, age at index, culture date, therapies (oral
and inhaled antibiotics, intravenous antibiotic-treated exacerba-
tions, oral and inhaled bronchodilators, oral and inhaled cortico-
steroids, mast cell stabilizers, oral, enteral, and parenteral
supplements, airway clearance techniques, pancreatic enzymes,
insulin, oxygen, and dornase alfa), diagnosis of allergic broncho-
pulmonary aspergillosis, elevated liver function tests, and pres-
ence of other bacteria in most recent respiratory tract culture
(PA, Staphylococcus aureus [SA], Haemophilus, Stenotropho-
monas maltophilia [SM], Burkholderia cepacia, other Gram-
negative organisms, Aspergillus, and Candida). All variables
were assessed as time-varying covariates, except gender and
age at index culture, which were time independent. A two-sided
p value b0.05 was considered statistically significant.3. Results
Of the 32,585 patients enrolled in ESCF from 1994 to 2005,
13,958 patients (comprising 51,374 patient-years) had at least
one respiratory-tract culture per year in each of the 5 calendar
years associated with any of the index years (1996–2003). Of
these patients, 4349 met the remainder of the culture and PFT
criteria outlined in the Section 2; 1111 patients had new
MARPA detected (MARPA+), and 3238 remained MARPA
negative (Fig. 2). The annual incidence of MARPA conversion
in patients who were PA positive ranged from 6.2% to 9.2%
(mean=7.5%), and it did not change significantly over time
(p=0.72). Table 1 shows the clinical features of MARPA-
positive patients compared with MARPA-negative patients at
the index date. The mean age in both groups was similar at
about 19 years, but there were significantly more young pa-
tients (age 6–11 years) in the MARPA-negative group
(pb0.001, data not shown). MARPA-positive patients had
mean FEV1 values that were 10% predicted points significantly
lower lung function than the MARPA-negative patients
(pb0.001), a 15% relative reduction. They were also more like-
ly to be treated with antibiotics by any route or receive other CF
therapies, such as dornase alfa.
The results of our primary outcome measure analysis of
FEV1 decline are shown in Fig. 3. FEV1 decline in MARPA-
positive patients was −2.22% predicted/year before the index
event of MARPA detection and −2.43% predicted/year after
detection, a difference in slope that was not significant
(p=0.45). To control for the possibility that new MARPA de-
tection was associated with an acute change in FEV1 that may
have been associated with more aggressive therapy, we also an-
alyzed a model that allowed for discontinuities around the
index event. We found no difference in our results using a dis-
continuous model. MARPA detection tended to be a transient
event for some patients. In 36.3% of patients, subsequent cul-
tures over the next 2 years were all negative for MARPA. To
Fig. 2. Derivation of the MARPA-positive and MARPA-negative cohorts.
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included in our analysis of persistent MARPA infection, we an-
alyzed FEV1 decline in transient MARPA and persistent
MARPA patients (Table 2). We found no significant difference
in FEV1 decline between these two groups.
Use of all CF therapies increased similarly over time for both
groups, but the use of enteral supplements and oxygen increased
even more in the MARPA-positive group compared with the
MARPA-negative group (Table 3). Enteral supplement useTable 1
Clinical features of the MARPA-positive and MARPA-negative cohorts. Unless
otherwise noted, values in parentheses represent %. Aspergillus status refers to a
positive culture and not the diagnosis of allergic bronchopulmonary aspergillosis.
Feature MARPA
Positive
MARPA
Negative
p
n 1111 3238
Age at index culture (SD), year 19.7 (8.54) 19.1 (9.03) 0.064
Gender
Male 551 (50.9) 1273 (49.3) 0.40
Female 532 (49.1) 1307 (50.7)
Mean FEV1% predicted (SD) 60.5 (23.8) 70.8 (25.3) b0.001
Mean number of cultures/years (SD) 3.4 (1.6) 2.8 (1.3) b0.001
Mean Body Mass Index Z Score (SD) −0.632 (1.15) −0.555 (1.44) 0.121
Other organisms
MRSA 55 (8.8) 68 (6.6) 0.10
S. maltophilia 60 (5.4) 71 (4.1) 0.093
B. cepacia 23 (2.1) 38 (2.2) 0.86
Aspergillus 144 (13.0) 181 (0.3) 0.031
Treatment
Intravenous antibiotic-treated
exacerbations
505 (45.5) 592 (18.3) b0.001
Oral antibiotics 155 (14.3) 293 (11.4) 0.013
Inhaled antibiotics 481 (44.4) 795 (30.8) b0.001
Oral corticosteroids 222 (20.5) 297 (11.5) b0.001
Inhaled corticosteroids 486 (44.9) 935 (36.2) b0.001
Dornase alfa 844 (76.0) 2173 (67.1) b0.001
Supplemental oxygen 133 (12.3%) 125 (4.8%) b0.001
FEV1, forced expiratory volume in 1 second; MARPA, multiple antibiotic-
resistant Pseudomonas aeruginosa, MRSA, methicillin-resistant Staphylococ-
cus aureus; SD, standard deviation.increased from 17% to 25% in MARPA-positive patients com-
pared with 9% to 15% in the MARPA-negative group
(p=0.017). The percentage of patients who ever received supple-
mental oxygen therapy increased from 17% to 29% in the
MARPA-positive group vs 8% to 16% in the MARPA-negative
group (p=0.002).
The assessment of MARPA by FEV1 quartile described in
the Methods revealed that the prevalence of MARPA was sim-
ilar between the upper and lower quartile sites (25.8% vs
25.7%, p=0.96), with no relationship between FEV1 quartile
and FEV1 decline before and after MARPA detection, regard-
less of age and baseline disease stage.
4. Discussion
The development of antibiotic-resistant bacteria is of con-
cern to CF clinicians and researchers [17]. In this analysis of
a large observational study of patients with CF, new MARPA
detection was not associated with a change in FEV1 decline.
Analyses based on persistence of infection and site FEV1Fig. 3. Relationship between incident MARPA detection and FEV1 decline. The
mean rates of FEV1 decline were estimated for the 2 years prior to and after the
index event of MARPA detection in the MARPA+group. FEV1 represents the
mean value up to and including the index event. Error bars represent ±1 SD.
Table 2
FEV1 decline in MARPA negative, transient MARPA, and persistent MARPA patients.
Patient Group FEV1 slope before exclusion period
(% predicted/year)
FEV1 slope after exclusion period
(% predicted/year)
p
MARPA negative −1.77 −2.45 b0.001
Transient MARPA −2.12 −2.41 0.349
Persistent
MARPA
−2.64 −2.62 0.977
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and FEV1 decline.
It is difficult to compare the results of our study with those
of other studies of MARPA, because of the varying definition
of multiple antibiotic resistance. The US CF Foundation guide-
lines define MARPA as resistance to all agents tested in two or
more of the following antibiotic classes: beta-lactams, amino-
glycosides, and quinolones [17]. Our definition required ami-
noglycoside and beta-lactam resistance, but did not require
resistance to all agents tested. Not all authors have applied the
US CFF definition, and even the CF Foundation (CFF) Patient
Registry only began collecting data using this definition in
2004. Similar to our findings with the ESCF definition of
MARPA, the prevalence of CFF-defined MARPA has not
changed from 2004 to the present [18]. In their analysis using
the CFF Registry, Merlo et al. used a very narrow definition
of MARPA (resistance to at least two of the following antibi-
otics: tobramycin, ciprofloxacin, or meropenem) and found
that the prevalence of MARPA rose steadily from 1998 to
2002 [2]. However, the Emerson et al. analysis of the CFF Reg-
istry compared a historical cohort of patients with CF in 1998
with a contemporary cohort in 2008 and found no change in
MARPA prevalence after adjusting for age and baseline FEV1
using the CFF definition [15]. Consistent with other studies of
antibiotic resistance in CF [4,16,19–22], we found that antibi-
otic use was highly associated with the likelihood of acquiring
MARPA.Table 3
Use of other therapies before and after the index date.
Variable Group Before
mean (
Oral antibiotics (percent of encounters) MARPA+ 5.87%
MARPA− 7.37%
Inhaled antibiotics (percent of encounters) MARPA+ 22.46%
MARPA− 18.80%
Oral corticosteroids (percent of encounters) MARPA+ 13.86%
MARPA− 10.49%
Enteral supplements (percent of encounters) MARPA+ 12.19%
MARPA− 7.41%
Insulin/oral hypoglycemic (percent of encounters) MARPA+ 0.12%
MARPA− 0.19%
Dornase alfa (percent of encounters) MARPA+ 75.70%
MARPA− 65.62%
Oxygen (percent of patients ever) MARPA+ 17.37%
MARPA− 8.09%
SE, standard error.
a Compares before to after within MARPA group.
b Compares difference between MARPA groups.Similar to the pattern observed for SM and methicillin-
resistant SA [19,20,22], we found that MARPA infection was
frequently a transient phenomenon, and only a small minority
of patients remained consistently MARPA positive after the ini-
tial detection. Possible explanations for this finding include re-
version of antibiotic sensitivity after selective pressure of
antibiotic therapy is gone, acquisition of a new PA strain, or
simple failure to recover MARPA consistently from respiratory
cultures. We have no information on the sensitivity and repro-
ducibility of the MARPA assays used at the various sites partic-
ipating in ESCF. Regardless of the reasons for transient
MARPA detection, we observed no effect of new MARPA de-
tection on FEV1 decline, even in chronically infected patients.
Only one other study has analyzed the impact of MARPA on
clinical outcomes, and it was performed at a single adult CF
center that also served as a referral site for lung transplantation.
Letchzin et al. reported that the presence of MARPA was asso-
ciated with a higher risk of death, a greater likelihood of need
for lung transplantation, and more rapid rate of FEV1 decline
compared with MARPA-negative adult CF patients, but their
study was not designed to assess the impact of new MARPA
detections on subsequent FEV1 decline [5]. In our study,
which included data from N200 pediatric and adult sites across
North America, we also found that MARPA was associated
with more rapid FEV1 decline. We also have made the novel
and important observation that MARPA acquisition does not
result in a significant change in FEV1 decline, suggesting thatexclusion period,
SE)
After exclusion period,
mean (SE)
p a p b
(0.4%) 18.43% (0.97%) b0.001 0.14
(0.33%) 18.18% (0.57%) b0.001
(0.76%) 39.54% (1.05%) b0.001 0.44
(0.45%) 36.75% (0.65%) b0.001
(0.82%) 15.89% (0.92%) 0.016 0.58
(0.46%) 11.98% (0.50%) 0.002
(1.01%) 18.69% (1.18%) b0.001 0.051
(0.51%) 11.85% (0.64%) b0.001
(0.05%) 4.08% (0.53%) b0.001 0.28
(0.04%) 3.51% (0.33%) b0.001
(1.18%) 80.75% (1.06%) b0.001 0.002
(0.83%) 74.65% (0.75%) b0.001
(1.14%) 29.43% (1.37%) b0.001 0.002
(0.48%) 15.66% (0.64%) b0.001
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rather than an independent contributor to worsening disease.
Our results are consistent with other data regarding CF mi-
crobiology and care. Although the acquisition of some
antibiotic-resistant bacteria is associated with worsening FEV1
decline [19,23], this does not happen in all cases [20,24]. The
lack of association between in vitro antibiotic susceptibility
and clinical response has been previously described [8–10].
Virulence of organisms may be determined by factors other
than antibiotic resistance patterns. It may also be that the com-
prehensive treatment for CF exacerbation results in clinical im-
provement independent of the bactericidal impact of antibiotics
used [8].
As with any study utilizing observational data, there are limi-
tations to our analysis. There are no specific microbiology proto-
cols in ESCF, so specimen processing may not be consistent
across all sites [25]. However, the majority of patients are fol-
lowed at CFF-accredited care centers, which are required to ad-
here to CFF guidelines for handling CF microbiology
specimens and undergo regular site visits to ensure compliance
with this practice. Because ESCF was initiated shortly before
the wide availability of oral quinolones, the definition of
MARPA was defined as resistance to both aminoglycosides and
beta-lactams [11]. This makes comparison of our analysis to pre-
vious studies difficult, but other studies have also used definitions
that differ from the current CFF guideline definition of MARPA
[2]. The prevalence of ciprofloxacin resistance has not changed
significantly in 2008 compared with 1995 [15]. This observation
suggests that mostMARPA has arisen because of development of
aminoglycoside or beta-lactam resistance. We adjusted for a large
number of potential confounders including all the available con-
founding therapies, co-morbid conditions, and other bacterial in-
fections However, as with any observational study, there could be
unmeasured confounders limiting the sensitivity of our analysis.
In summary, our analysis of ESCF data does not demon-
strate an impact of MARPA acquisition on FEV1 decline. Rath-
er, MARPA appears to be a marker of an advanced stage of
lung disease and the need for antibiotic therapy in patients
with CF. Future studies should focus on molecular and genetic
factors that may contribute to increased virulence of PA regard-
less of antibiotic resistance patterns, and on determining ratio-
nal and clinically relevant treatment regimens for CF patients
infected with MARPA, such as nutritional support, oxygen sup-
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